<span item_type="fundamental" item_id="21b69c0a4fb761bc503e8b8f1bdcd8c2" counter_id="ST/US/ALCYW" env="prod"></span><span item_type="announcement" item_id="518290682121094785" env="prod"></span><p>EPS: As of FY2025 Q1, the actual value is USD -0.07.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not commenced any operations and has not generated any operating revenues as of March 31, 2025. The company will generate non-operating income in the form of investment income on cash and cash equivalents from the proceeds derived from the Initial Public Offering.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: For the three months ended March 31, 2025, the company reported a net loss of $301,497, compared to a net income of $1,413,829 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li><li><strong>Operating Costs</strong>: Operating and formation costs were $401,439 for the three months ended March 31, 2025, compared to $163,825 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: For the three months ended March 31, 2025, net cash used in operating activities was $429,175, compared to $180,531 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: For the three months ended March 31, 2025, net cash provided by financing activities was $600,000, due to the proceeds from the promissory note, related party.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Gain on Investments Held in Trust Account</strong>: The company reported a gain on investments held in the Trust Account of $124,408 for the three months ended March 31, 2025, compared to $1,573,981 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to address its going concern uncertainty with the successful closing of a Business Combination. The company had until November 9, 2024, to consummate a Business Combination, which was extended to September 9, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is in the process of identifying a potential company for an initial Business Combination but requires additional time. The company has extended its deadline for consummating a Business Combination to September 9, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1901336/000141057825001371/alcy-20250331x10q.htm"></span></li></ul>

ALCHEMY INVTS ACQUISITION CORP 1 C/WTS 30/11/2027 (TO PUR ORD) | 10-Q: FY2025 Q1 EPS: USD -0.07